SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                   -------------------------------------------


                                    FORM 8-K


                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934



                                 Date of Report
                       (Date of earliest event reported):

                                   May 3, 1999

                    ----------------------------------------


                            TREX MEDICAL CORPORATION
             (Exact name of Registrant as specified in its charter)


Delaware                        1-11827                   06-1439626
(State or other               (Commission              (I.R.S. Employer
jurisdiction of               File Number)             Identification Number) 
incorporation or 
organization)


37 Apple Ridge Road
Danbury, Connecticut                                        06810
(Address of principal executive offices)                  (Zip Code)


                                 (203) 207-4500
                         (Registrant's telephone number
                              including area code)



<PAGE>








      This Form 8-K contains forward-looking statements that involve a number of
risks and  uncertainties.  Important  factors that could cause actual results to
differ  materially from those indicated by such  forward-looking  statements are
set forth under the heading  "Forward-looking  Statements" in Exhibit 13 to Trex
Medical  Corporation's  Annual Report on Form 10-K for the year ended October 3,
1998, as amended.  These include risks and uncertainties relating to: dependence
on capital spending policies,  technological change and new product development,
the Registrant's  acquisition  strategy,  intense competition,  patent and other
litigation,  development and  commercialization  of products under  development,
compliance  with  government  regulations,  the need for  regulatory  approvals,
healthcare  reform and  uncertainty  of  patient  reimbursement,  dependence  on
patents and  proprietary  rights,  dependence  on OEM  relationships,  potential
product  liability,  international  operations,  and the potential impact of the
year 2000 on processing date-sensitive information.

Item 5.     Other Events

      On May 3, 1999, the Registrant  issued a press release  announcing that it
will record pretax  restructuring  and other charges totaling  approximately $11
million.  Approximately  $6  million  to $7  million  will  be  recorded  in the
Registrant's  third fiscal quarter,  which ends July 3, 1999, with the remainder
recorded as costs are incurred over the next several  quarters.  The majority of
the charges will be incurred as a result of the  Registrant's  decision to close
two of  its  four  domestic  manufacturing  facilities  after  relocating  these
operations,  and, to a lesser extent,  as a result of actions to reduce costs in
other operations. This process will result in a staff reduction of approximately
15 percent.  The  Registrant  estimates that these actions will result in fiscal
2000 operating savings of approximately $4 million to $5 million.

      The  Registrant's  Bennett  facility  in  Copiague,   New  York,  and  its
Continental facility in Broadview, Illinois, will be closed. Sales and marketing
offices  for  Bennett  and  Continental   will  remain  in  these   communities.
Manufacturing and product  development of the Registrant's  mammography  systems
will now be concentrated at the  Registrant's  Danbury,  Connecticut,  site. All
manufacturing and product  development of general-purpose  and other specialized
X-ray   systems   will  now  be  conducted   at  the   Registrant's   Littleton,
Massachusetts,  facility.  The  Registrant  will  continue  to  manufacture  its
complete  product line and market its systems  under its four  existing  product
line names: Lorad, Bennett,  Continental, and XRE. Distribution channels will be
maintained as before.
<PAGE>


Item 7.     Financial Statements, Pro Forma Financial Information and Exhibits

      (a)   Financial Statements of Business Acquired: not
            applicable.

      (b)   Pro Forma Financial Information: not applicable.

      (c)   Exhibits: not applicable.




<PAGE>



                                    SIGNATURE



      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized, on this 5th day of May, 1999.



                                          TREX MEDICAL CORPORATION


                                          By:/s/ Theo Melas-Kyriazi
                                             -----------------------------
                                             Theo Melas-Kyriazi
                                             Chief Financial Officer
[{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 5051}]
{"company-data": {"conformed-name": "TREX MEDICAL CORP", "cik": "0001003539", "assigned-sic": "3844", "irs-number": "061439626", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11827", "film-number": "99611210"}, "business-address": {"street1": "37 APPLE RIDGE RD", "street2": "P.O. BOX 9046", "city": "DANBURY,", "state": "CT", "zip": "06810", "phone": "2037901188"}, "mail-address": {"street1": "81 WYMAN STREET", "street2": "P.O. BOX 9046", "city": "WALTHAM", "state": "MA", "zip": "02254"}}
SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                   -------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                 Date of Report
                       (Date of earliest event reported):

                                   May 3, 1999

                    ----------------------------------------

                            TREX MEDICAL CORPORATION
             (Exact name of Registrant as specified in its charter)

Delaware                        1-11827                   06-1439626
(State or other               (Commission              (I.R.S. Employer
jurisdiction of               File Number)             Identification Number) 
incorporation or 
organization)

37 Apple Ridge Road
Danbury, Connecticut                                        06810
(Address of principal executive offices)                  (Zip Code)

                                 (203) 207-4500
                         (Registrant's telephone number
                              including area code)
This Form 8-K contains forward-looking statements that involve a number of
risks and  uncertainties.  Important  factors that could cause actual results to
differ  materially from those indicated by such  forward-looking  statements are
set forth under the heading  "Forward-looking  Statements" in Exhibit 13 to Trex
Medical  Corporation's  Annual Report on Form 10-K for the year ended October 3,
1998, as amended.  These include risks and uncertainties relating to: dependence
on capital spending policies,  technological change and new product development,
the Registrant's  acquisition  strategy,  intense competition,  patent and other
litigation,  development and  commercialization  of products under  development,
compliance  with  government  regulations,  the need for  regulatory  approvals,
healthcare  reform and  uncertainty  of  patient  reimbursement,  dependence  on
patents and  proprietary  rights,  dependence  on OEM  relationships,  potential
product  liability,  international  operations,  and the potential impact of the
year 2000 on processing date-sensitive information.

Item 5.     Other Events

      On May 3, 1999, the Registrant  issued a press release  announcing that it
will record pretax  restructuring  and other charges totaling  approximately $11
million.  Approximately  $6  million  to $7  million  will  be  recorded  in the
Registrant's  third fiscal quarter,  which ends July 3, 1999, with the remainder
recorded as costs are incurred over the next several  quarters.  The majority of
the charges will be incurred as a result of the  Registrant's  decision to close
two of  its  four  domestic  manufacturing  facilities  after  relocating  these
operations,  and, to a lesser extent,  as a result of actions to reduce costs in
other operations. This process will result in a staff reduction of approximately
15 percent.  The  Registrant  estimates that these actions will result in fiscal
2000 operating savings of approximately $4 million to $5 million.

      The  Registrant's  Bennett  facility  in  Copiague,   New  York,  and  its
Continental facility in Broadview, Illinois, will be closed. Sales and marketing
offices  for  Bennett  and  Continental   will  remain  in  these   communities.
Manufacturing and product  development of the Registrant's  mammography  systems
will now be concentrated at the  Registrant's  Danbury,  Connecticut,  site. All
manufacturing and product  development of general-purpose  and other specialized
X-ray   systems   will  now  be  conducted   at  the   Registrant's   Littleton,
Massachusetts,  facility.  The  Registrant  will  continue  to  manufacture  its
complete  product line and market its systems  under its four  existing  product
line names: Lorad, Bennett,  Continental, and XRE. Distribution channels will be
maintained as before.
Item 7.     Financial Statements, Pro Forma Financial Information and Exhibits

      (a)   Financial Statements of Business Acquired: not
            applicable.

      (b)   Pro Forma Financial Information: not applicable.

      (c)   Exhibits: not applicable.
SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized, on this 5th day of May, 1999.

                                          TREX MEDICAL CORPORATION

                                          By:/s/ Theo Melas-Kyriazi
                                             -----------------------------
                                             Theo Melas-Kyriazi
                                             Chief Financial Officer